We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Daiichi Sankyo Files NDA in Japan for Marketing of the Methylene Blue Injection Medicinal Product
News

Daiichi Sankyo Files NDA in Japan for Marketing of the Methylene Blue Injection Medicinal Product

Daiichi Sankyo Files NDA in Japan for Marketing of the Methylene Blue Injection Medicinal Product
News

Daiichi Sankyo Files NDA in Japan for Marketing of the Methylene Blue Injection Medicinal Product

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Daiichi Sankyo Files NDA in Japan for Marketing of the Methylene Blue Injection Medicinal Product"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Provepharm has announced that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm’s Proveblue® Methylene Blue active substance.

In November 2011, Provepharm out-licensed to Daiichi Sankyo the exclusive rights for developing and marketing its medicinal product in Japan. It is already approved by the European Medicines Agency for the treatment of metheamoglobinaemia induced by medicinal and chemical products. It is traded in Europe as ’Methylthioninium chloride Proveblue 5mg/ml solution for injection’.

Methylene Blue is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs set up by the Ministry of Health, Labour and Welfare in Japan. Daiichi Sankyo is committed to making this drug available to Japanese patients waiting for it to be approved.

Advertisement